Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Stauber, RE; Hofer, H; Hackl, F; Schütze, K; Datz, C; Hegenbarth, K; Jessner, W; Steindl-Munda, P; Peter, F; Austrian Hepatitis Study Group.
Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
WIEN KLIN WOCHENSCHR. 2004; 116(15-16): 530-535.
Doi: 10.1007/BF03217706
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Stauber Rudolf
- Co-Autor*innen der Med Uni Graz
- Hegenbarth Karin
- Hofer Herwig
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- There is currently no accepted therapeutic regimen for patients with chronic hepatitis C who failed to respond to standard combination treatment with interferon-alpha plus ribavirin. We investigated triple combination treatment with induction dosing of interferon-alpha plus ribavirin plus amantadine in these difficult-to-treat patients. Nonresponders (n = 67), breakthroughs (n = 16) and relapsers (n = 19) to previous interferon/ribavirin combination treatment of at least 6 months were included. For the first 16 weeks, patients received interferon-alpha2a 6 MU daily, ribavirin 800-1200 mg/d, and amantadine 200 mg/d. In cases of undetectable HCV RNA at week 12, treatment was continued with interferon-alpha2a 6 MU every other day and the same doses of ribavirin and amantadine until week 48. In cases of HCV RNA positivity at week 12, treatment was stopped. A total of 102 patients were enrolled (80%: genotype 1, 19%: cirrhosis). HCV RNA was negative in 35/102 patients (34%) at week 12 and in 27/ 102 patients (26%) at the end of treatment. Virological response was sustained in 15/102 patients (15%). On-treatment virological response was higher in previous relapsers/breakthroughs than in previous nonresponders (week 12: 49% vs. 27%, p < 0.05; week 48: 46% vs. 16%, p < 0.01) but no such difference was found for sustained virological response (20% vs. 12%, NS). In conclusion, triple combination treatment with daily interferon-alpha plus ribavirin plus amantadine for 3 months can induce virological response in a considerable number of nonresponders/relapsers to previous dual combination treatment, but the sustained virological response rate remains low.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Amantadine - administration and dosage
- Antiviral Agents - administration and dosage
- Austria - epidemiology
- Dose-Response Relationship, Drug - epidemiology
- Drug Combinations - epidemiology
- Drug Tolerance - epidemiology
- Female - epidemiology
- Hepatitis C, Chronic - drug therapy
- Humans - drug therapy
- Interferon-alpha - administration and dosage
- Male - administration and dosage
- Middle Aged - administration and dosage
- Recurrence - prevention and control
- Ribavirin - administration and dosage
- Treatment Failure - administration and dosage
- Treatment Outcome - administration and dosage
- Find related publications in this database (Keywords)
- chronic hepatitis C
- nonresponders
- induction treatment
- interferon-alpha
- ribavirin
- amantadine